Pfizer announced a new alliance with Sarah Cannon Research Institute to accelerate oncology trials and granted Rigel rights to commercialize VEPPANU, a breast cancer therapy. The stock is down over 50% from 2021 highs, seen as undervalued by hedge funds, but has shown little upside recently. Partner Kelun-Biotech reported positive trial results for a Keytruda combo in lung cancer, and EU approval was granted for HYMPAVZI in hemophilia.